YIH
CRNX icon

Y-Intercept (HK)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Y-Intercept (HK)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,738
Closed -$240K – 1426
2023
Q4 		$240K Buy
+6,738
New +$207K 0.02% 911

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Y-Intercept (HK)'s CRNX Position: Q1 2024 in Review

Y-Intercept (HK) sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 6,738 shares — an estimated $240K sold.

Y-Intercept (HK) first reported a position in CRNX in Q4 2023 and held it in 1 quarter. The position peaked at $240K in Q4 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

  • Y-Intercept (HK) reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 6,738 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $240K.
  • Y-Intercept (HK) first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s Crinetics Pharmaceuticals position peaked at $240K in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.